References
Can, G., Aydiner, A., & Cavdar, I. (2012). Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. European Journal of Oncology Nursing, 16, 270-275. doi:10.1016/j.ejon.2011.06.007
Chew, L., & Chuen, V. S. (2009). Cutaneous reaction associated with weekly docetaxel administration. Journal of Oncology Pharmacy Practice, 15, 29-34. doi:10.1177/1078155208096111
Chitapanarux, I., Kamnerdsupaphon, P., Tharavichitkul, E., Lorvidhaya, V., Trakultivakorn, H., Srisukho, S., … Sukthomya, V. (2012). Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 8, 76-82. doi:10.1111/j.1743-7563.2011.01467.x
Daniel, C. R., 3rd, Daniel, M. P., Daniel, J., Sullivan, S., & Bell, F. E. (2004). Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen. Cutis: Cutaneous Medicine for the Practitioner, 73, 81-85.
DeGiorgi, U., Rosti, G., Monti, M., Frassineti, G. L., & Marangolo, M. (2003). Onycholysis secondary to multiple paclitaxel one-hour infusions: Possible role for its vehicle (Cremophor EL). Annals of Oncology, 14, 1588-1589. doi:10.1093/annonc/mdg419
Flory, S. M., Solimando, D. A., Jr., Webster, G. F., Dunton, C. J., Neufeld, J. M., & Haffey, M. B. (1999). Onycholysis associated with weekly administration of paclitaxel. Annals of Pharmacotherapy, 33, 584-586. doi:10.1345/aph.18307
Ghetti, E., Piraccini, B. M., & Tosti, A. (2003). Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). Journal of European Academy of Dermatology and Venereology, 17, 459-460. doi:10.1046/j.1468-3083.2003.00774.x
Gilbar, P., Hain, A., & Peereboom, V. M. (2009). Nail toxicity induced by cancer chemotherapy. Journal of Oncology Pharmacy Practice, 15, 143-155. doi:10.1177/1078155208100450
Gori, S., Colozza, M., Mosconi, A. M., Franceschi, E., Basurto, C., Cherubini, R., … Tonato, M. (2004). Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer, 90, 36-40.
Hussain, S., Anderson, D. N., Salvatti, M. E., Adamson, B., McManus, M., & Braverman, A. S. (2000). Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer, 88, 2367-2371. doi:10.1002/(SICI)1097-0142 (20000515)88:10
Mackay-Wiggan, J., Nair, K. G., & Halasz, C. L. (2003). Onycholysis associated with paclitaxel. Cutis: Cutaneous Medicine for the Practitioner, 71, 229-232.
Markman, M., Hall, J., Spitz, D., Weiner, S., Carson, L., Van Le, L., … Baker, M. (2002). Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. Journal of Clinical Oncology, 20, 2365-2369. doi:10.1200/JCO.2002.09.130
Mauri, D., Kamposioras, K., Tsali, L., Bristianou, M., Valachis, A., Karathanasi, I., … Polyzos, N. P. (2010). Overall survival benefit for weekly versus three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treatment Review, 36, 69-74. doi:10.1016/j.ctrv.2009.10.006
Miladinovic, D. L., Mihajilov-Krstev, T. M., Nikolic, N. D., Miladinovic, L. C., & Cvetkovic, O. G. (2012). Investigation of the chemical composition-antibacterial activity relationship of essential oils by chemometric methods. Analytical and Bioanalytical Chemistry, 403, 1007-1018. doi:10.1007/s00216-012-5866-1
Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., … Puglisi, F. (2003). Taxane-induced nail changes: Incidence, clinical presentation and outcome. Annals of Oncology, 14, 333-337. doi:10.1093/annonc/mdg050
Minutilli, E., Izzo, F., Natoli, G., Psaila, A., DiFilippo, F., & Terzoli, E. (2006). Paclitaxel-induced nail changes: Possible role of its vehicle (Cremophor EL). European Journal of Dermatology, 16, 693-694.
Paul, L. J., & Cohen, P. R. (2012). Paclitaxel-associated subungual pyogenic granuloma: Report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. Journal of Drugs in Dermatology, 11, 262-268.
Roh, M. R., Cho, J. Y., & Lew, W. (2007). Docetaxel-induced onycholysis: The role of subungual hemorrhage and suppuration. Yonsei Medical Journal, 48, 124-126. doi:10.3349/ymj.2007.48.1.124
Scotte, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., … Oudard, S. (2008). Matched case control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer, 112, 1625-1631. doi:10.1002/cncr.23333
Shin, E., Ishotobi, M., Hiraoia, M., Kazumasa, F., Hideyuki, M., Nishisho, I., … Tosimasa, T. (2000). Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer. Anticancer Research, 20(6C), 4721-4726.
Sorbe, B., Graflund, M., Horvath, G., Swahn, M., Boman, K., Bangshoj, R., … Malmstrom, H. (2012). Phase II study of docetaxel weekly in combination with carboplatin every three weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer. International Journal of Gynecological Cancer, 22, 47-53.
Wasner, G., Hilpert, F., Schattschneider, J., Binder, A., Pfisterer, J., & Baron, R. (2002). Docetaxel-induced nail changes—A neurogenic mechanism: A case report. Journal of Neuro-Oncology, 58, 167-174.